ChromaDex Corp (NAGE) Stock Forecast & Price Target

Niagen Bioscience is a leader in NAD+ science and healthy aging research, with clinically proven products that efficiently increase NAD+ levels. The company recently reported strong 1Q26 financial results, with moderate revenue outperformance and in-line earnings. They have a well-established product portfolio and a favorable market outlook, with projected sales growth in the anti-aging and longevity markets. Risks include slower sales growth, unfavorable clinical data, and increased competition, but potential opportunities such as a pen-like autoinjector and ongoing research in NAD+ related diseases could drive future growth. Overall, Niagen Bioscience presents an attractive investment opportunity with a strong brand reputation and focus on innovation in the health and wellness sector.

Niagen Bioscience is a company that has yet to produce a successful product in the market despite its promising technology and research in NAD+ boosting solutions. The company's low probability of getting their products on the market and high discount rate contribute to a negative outlook as it raises concerns about their ability to generate revenue and reach profitability. Their estimated enterprise value of $393M also does not fully justify the risks associated with investing in this company.